3. Grades of port complications and their correlation with clinical characteristics (N=57).
| Variables | N | Complications [n (%)] | P | |||
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |||
| BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; PCI, peritoneal cancer index; Yes, gastrectomy plus with port implantation; No, port implantation only; LS, laparoscopic exploration surgery; Open, port implanted with open surgery; Before, before the optimization of port implantation procedure; After, after the optimization of port implantation procedure; *, Mann-Whitney U test; **, Goodman-Kruskal Gamma test. | ||||||
| Sex | 0.302* | |||||
| Male | 20 | 4 (7.0) | 7 (12.3) | 2 (3.5) | 7 (12.3) | |
| Female | 37 | 16 (28.1) | 5 (8.8) | 5 (8.8) | 11 (19.3) | |
| Age (year) | 0.172* | |||||
| <60 | 42 | 18 (31.6) | 6 (10.5) | 6 (10.5) | 12 (21.1) | |
| ≥60 | 15 | 2 (3.5) | 6 (10.5) | 1 (1.8) | 6 (10.5) | |
| BMI (kg/m2) | 0.333* | |||||
| <23 | 36 | 14 (24.6) | 8 (14.0) | 4 (7.0) | 10 (17.5) | |
| ≥23 | 21 | 6 (10.5) | 4 (7.0) | 3 (5.3) | 8 (14.0) | |
| ECOG PS | 0.016** | |||||
| 0 | 11 | 9 (15.8) | 1 (1.8) | 0 (0) | 1 (1.8) | |
| 1 | 36 | 9 (15.8) | 8 (14.0) | 5 (8.8) | 14 (24.6) | |
| 2 | 10 | 2 (3.5) | 3 (5.3) | 2 (3.5) | 3 (5.3) | |
| PCI | 0.886** | |||||
| 0−10 | 9 | 2 (3.5) | 2 (3.5) | 0 (0) | 5 (8.8) | |
| 11−20 | 20 | 9 (15.8) | 4 (7.0) | 3 (5.3) | 4 (7.0) | |
| 21−39 | 28 | 9 (15.8) | 6 (10.5) | 4 (7.0) | 9 (15.8) | |
| Ascites | 0.173* | |||||
| Present | 54 | 20 (35.1) | 11 (19.3) | 7 (12.3) | 16 (28.1) | |
| Absent | 3 | 0 (0) | 1 (1.8) | 0 (0) | 2 (3.5) | |
| Prior chemotherapy | 0.804* | |||||
| Present | 19 | 6 (10.5) | 3 (5.3) | 5 (8.8) | 5 (8.8) | |
| Absent | 38 | 14 (24.6) | 9 (15.8) | 2 (3.5) | 13 (22.8) | |
| Simultaneous surgery | 0.316* | |||||
| Yes | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (1.8) | |
| No | 56 | 20 (35.1) | 12 (21.1) | 7 (12.3) | 17 (29.8) | |
| Albumin (g/L) | 0.745* | |||||
| <35 | 28 | 11 (19.3) | 5 (8.8) | 3 (5.3) | 9 (15.8) | |
| ≥35 | 29 | 9 (15.8) | 7 (12.3) | 4 (7.0) | 9 (15.8) | |
| Hemoglobin | 0.300* | |||||
| Anemia | 35 | 11 (19.3) | 7 (12.3) | 4 (7.0) | 13 (22.8) | |
| Normal | 22 | 9 (15.8) | 5 (8.8) | 3 (5.3) | 5 (8.8) | |
| Glucose | 0.360* | |||||
| Euglycemia | 50 | 20 (35.1) | 8 (14.0) | 6 (10.5) | 16 (28.1) | |
| Hyperglycemia | 7 | 0 (0) | 4 (7.0) | 1 (1.8) | 2 (3.6) | |
| Implantation approach | 0.316* | |||||
| LS | 56 | 20 (35.1) | 12 (21.1) | 7 (12.3) | 17 (29.8) | |
| Open | 1 | 0 (0) | 0 (0) | 0 (0) | 1 (1.8) | |
| Implantation period | 0.677* | |||||
| Before | 38 | 15 (26.3) | 6 (10.5) | 5 (8.8) | 12 (21.1) | |
| After | 19 | 5 (8.8) | 6 (10.5) | 2 (3.6) | 6 (10.5) | |
| Implantation group | 0.853* | |||||
| Specialized group | 32 | 12 (21.1) | 6 (10.5) | 2 (3.6) | 12 (21.1) | |
| Other groups | 25 | 8 (14.0) | 6 (10.5) | 5 (8.8) | 6 (10.5) | |